By Robert King
HHS launched a major partnership with pharmacy chains and independent facilities to distribute a COVID-19 vaccine after it is approved.
read more
By Eric Sagonowsky
Months after drugmakers launched an unprecedented COVID-19 research effort, some existing medicines have turned in promising results—but more of them have failed against the virus. And AstraZeneca’s blood cancer med Calquence just became one of them, falling short in a test in hospitalized patients.
read more
By Paige Minemyer
The COVID-19 pandemic is accelerating trends impacting insurers' finances, in particular the interest in additional government control in the market, according to a new report from Fitch Ratings.
read more
By Ben Adams
After signing up to use GlaxoSmithKline’s adjuvant vaccine technology back in the summer, Canadian biotech Medicago has already finished off a phase1, and is now kicking on with several phase 2/3 trials.
read more
By Fraiser Kansteiner
As multiple COVID-19 shots edge close to the finish line, the focus is due to pivot to supply chain, Janssen's Paul Lefebvre figures. But thanks to J&J's expansive slate of manufacturing partners, the company is on track to meet its lofty manufacturing goals and has even started to weigh its pandemic plans for 2022.
read more
By Robert King
An Urban Institute analysis finds more than 3 million people lost their employer-sponsored insurance, spelling changes to the payer mix for providers.
read more
By Arlene Weintraub
Eli Lilly's COVID-19 antibody drug bamlanivimab won emergency authorization from the FDA with a label that's limited and potentially confusing, some analysts griped. Coupled with an expected onslaught of vaccines, those issues will likely suppress the potential market for antibody drugs from both Lilly and Regeneron, they said.
read more
By Eric Sagonowsky
With COVID-19 vaccines and therapeutics rapidly moving ahead, Johnson & Johnson CEO Alex Gorsky said there's not a competition among drugmakers, but a cooperative, industrywide effort to defeat the pandemic. The best scenario, as outlined by Gorsky during a Detroit Economic Club event? "Four or five or six of these vaccines" available next year.
read more
By Robert King
Payer and provider groups want Congress to extend a moratorium on Medicare sequester cuts that are now set to resume in January.
read more
By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner
CureVac isn't a frontrunner in the mRNA vaccine field, but its shot holds one advantage over the leading players. Medicago is pushing its plant-derived candidate into phase 3, incorporating GSK's adjuvant technology. Plus, analysts flagged concerns about potential antibody revenues from Eli Lilly and Regeneron.
read more
By Angus Liu
For an entirely new technology that hasn't seen a single approved product, Pfizer and BioNTech's COVID-19 vaccine victory showed mRNA can be quickly pivoted for a pandemic pathogen and will "open the floodgates" for its application in infectious disease. But other diseases? That could be a different story.
read more
